Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?

Six-Month Data Shows Visceral Fat Reduction And Lean Mass StabilityAt the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant placebo-adjusted reductions in visceral fat by 14%, total fat by 5%, and waist circumference by 3%, while stabilizing lean mass with a 2% increase.The results suggest that WVE-007 could lead to greater improvements in body composition compared to existing treatments, with the company expecting to initiate the Phase 2a multidose portion of INLIGHT in individu ...